All

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.
20 June 2024

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.

Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial. The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC)...

Read the press release
MaaT Pharma Launches a Global Offering of approximately 18 Million Euros
14 May 2024

MaaT Pharma Launches a Global Offering of approximately 18 Million Euros

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read more
Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis
2 May 2024

Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Khosla...

Read more
TransferGo raises $10M to expand its remittance business in Asia, doubling valuation
9 April 2024

TransferGo raises $10M to expand its remittance business in Asia, doubling valuation

The U.K.-based fintech best known as a consumer platform for global remittances, has raised a $10 million growth funding round from Taiwan-based investor Taiwania Capital, with...

Read more
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
8 April 2024

MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read more
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
25 March 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.

Read the press release
BlueTech Inalve announces the closing of a €4.7 million financing round
25 March 2024

BlueTech Inalve announces the closing of a €4.7 million financing round

The participation of the Blue Forward FundTM, managed by Seventure Partners, and the PSIM fund, managed by Bpifrance on behalf of the French government, confirms the strong...

Read the press release
Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
15 March 2024

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

The company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's...

Read more
Clinical Microbiomics adds long-read DNA&RNA sequencing with DNASense acquisition
1 March 2024

Clinical Microbiomics adds long-read DNA&RNA sequencing with DNASense acquisition

Danish contract research organisation Clinical Microbiomics today reveals the acquisition of DNASense, specializing in long-read DNA and RNA sequencing technologies and...

Read more